Abstract
There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.
| Original language | English |
|---|---|
| Pages (from-to) | 582-586 |
| Number of pages | 5 |
| Journal | Drug Development Research |
| Volume | 67 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Organic Chemistry
- Drug Discovery
- Pharmacology
Cite this
Postprandial hyperglycemia : Why do we care about it? What should we do? / Rendell, Marc S.
In: Drug Development Research, Vol. 67, No. 7, 07.2006, p. 582-586.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Postprandial hyperglycemia
T2 - Why do we care about it? What should we do?
AU - Rendell, Marc S.
PY - 2006/7
Y1 - 2006/7
N2 - There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.
AB - There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.
UR - http://www.scopus.com/inward/record.url?scp=33845201944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845201944&partnerID=8YFLogxK
U2 - 10.1002/ddr.20127
DO - 10.1002/ddr.20127
M3 - Article
VL - 67
SP - 582
EP - 586
JO - Drug Development Research
JF - Drug Development Research
SN - 0272-4391
IS - 7
ER -